Medpace Holdings, Inc.
NASDAQ•MEDP
CEO: Dr. August James Troendle M.D.
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 2016-08-11
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
連絡先情報
時価総額
$12.56B
PER (TTM)
28.0
21.3
配当利回り
--
52週高値
$628.92
52週安値
$250.05
52週レンジ
順位20Top 6.4%
6.1
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6.1 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$708.45M+0.00%
直近4四半期の推移
EPS
$4.78+0.00%
直近4四半期の推移
フリーCF
$0.00+0.00%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Nine Month Revenue Growth Nine months revenue reached $1.82B USD, marking a strong 15.9% increase compared to prior year period.
Quarterly Net Income Rises Q3 Net Income was $111.1M USD, showing $14.7M USD improvement over Q3 2024 results.
Strong Operating Income Performance Nine months income from operations totaled $381.7M USD, reflecting 15.1% growth compared to the prior year period.
Backlog Conversion Potential Total backlog stands at $3.00B USD as of September 30, 2025, a 2.5% increase from last year.
リスク要因
Significant Share Repurchase Cash Use Nine months financing cash flow used $883.1M USD, primarily due to $917.4M USD in common stock repurchases.
Cash Balance Reduction Cash and cash equivalents decreased to $285.4M USD from $669.4M USD since year-end 2024.
Higher Income Tax Provision Income tax provision increased $14.9M USD for nine months, due to lower FDII tax benefits.
Decreased Interest Income Nine months net interest income dropped $8.1M USD to $9.1M USD, driven by lower cash balances.
見通し
Remaining Share Repurchase Authority Remaining authorization for share repurchases stands at $821.7M USD under the current Board approved program.
New Tax Disclosure Adoption Expect adoption of ASU 2023-09 regarding income tax disclosures in the fourth quarter of fiscal year 2025.
Credit Facility Expiration Date Unsecured Credit Facility remains undrawn as of September 30, 2025; facility is set to expire April 30, 2027.
Purchase Commitments Visibility Minimum purchase commitments for supplies total $18.0M USD, expiring at various times through 2029.
同業比較
売上高 (TTM)
CNC$194.78B
FMS$21.68B
$20.86B
粗利益率 (最新四半期)
NBIX98.2%
70.6%
ILMN67.0%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| DGX | $22.96B | 23.0 | 13.9% | 39.3% |
| WAT | $19.47B | 30.3 | 28.5% | 0.0% |
| CNC | $19.47B | -2.9 | -27.7% | 22.7% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
8.2%
安定成長
4四半期純利益CAGR
5.6%
収益性の着実な向上
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年4月20日
EPS:$3.77
|売上高:-
財務レポート
財務データ
全年度
Form 10-K - FY 2025
会計期末: 2025年12月31日|提出日: 2026年2月10日|売上高: $2.53B+20.0%|EPS: $15.64+19.8%予想を上回るForm 10-Q - Q3 2025
会計期末: 2025年9月30日|提出日: 2025年10月23日|売上高: $659.90M+23.7%|EPS: $3.95+27.0%予想を上回るForm 10-Q - Q2 2025
会計期末: 2025年6月30日|提出日: 2025年7月22日|売上高: $603.31M+14.2%|EPS: $3.16+10.9%予想を上回るForm 10-Q - Q1 2025
会計期末: 2025年3月31日|提出日: 2025年4月22日|売上高: $558.57M+9.3%|EPS: $3.77+13.6%予想を上回るForm 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年2月11日|売上高: $2.11B+11.8%|EPS: $13.06+42.0%予想を上回るForm 10-Q - Q3 2024
会計期末: 2024年9月30日|提出日: 2024年10月22日|売上高: $533.32M+8.3%|EPS: $3.11+35.2%予想を上回るForm 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年7月23日|売上高: $528.10M+14.6%|EPS: $2.85+42.5%予想を上回るForm 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年4月23日|売上高: $511.04M+17.7%|EPS: $3.32+41.3%予想を上回る